Implementing Monte Carlo Dose Calculation in the Treatment of Non–small Cell Lung Cancer (NSCLC): Clinical Consequences

Zyp, N. van der Voort van; Hoogeman, M.; Heijmen, B.; Water, Steven van de; Nuyttens, J.

doi:10.1016/j.ijrobp.2009.07.1028

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from our study suggest that SBRT therapy in large > 5 cm primary NSCLC tumors is associated with acceptable rates of grade 2 or higher therapy-associated toxicities, comparable to reports on tumors < 5 cm. [2][3][4][5][6][7] Onishi et al 15 found 10.9% grade 2 or higher toxicities in 28 of 257 patients, and RTOG 0236 1 reported 15% grade 3 or higher toxicities. When judging causation for observed toxicities, it can be difficult to distinguish between disease progression and treatment effect, and this potential confounder should be recognized.…”

Section: Discussionmentioning

confidence: 98%